...
vxrt-img

Vaxart Inc, Common Stock

VXRT

NAQ

$0.563

-$0.03

(-5.08%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$134.37M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.25M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.70
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.52 L
$1.54 H
$0.563

About Vaxart Inc, Common Stock

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVXRTSectorS&P500
1-Week Return-11.92%-2.06%-0.55%
1-Month Return-11.48%-1.92%2.72%
3-Month Return-40.01%-10.4%7.66%
6-Month Return-21.01%-4.6%10.15%
1-Year Return-13.27%4.06%27.53%
3-Year Return-92.82%1.94%32.31%
5-Year Return80%36.48%89.2%
10-Year Return-97.95%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue9.86M4.05M892.00K107.00K7.38M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":41.03,"profit":true},{"date":"2021-12-31","value":9.04,"profit":true},{"date":"2022-12-31","value":1.08,"profit":true},{"date":"2023-12-31","value":74.82,"profit":true}]
Cost of Revenue14.54M19.86M48.75M3.27M68.14M[{"date":"2019-12-31","value":21.34,"profit":true},{"date":"2020-12-31","value":29.15,"profit":true},{"date":"2021-12-31","value":71.54,"profit":true},{"date":"2022-12-31","value":4.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(4.68M)(15.82M)(47.86M)(3.16M)(60.76M)[{"date":"2019-12-31","value":-467800000,"profit":false},{"date":"2020-12-31","value":-1581700000,"profit":false},{"date":"2021-12-31","value":-4785700000,"profit":false},{"date":"2022-12-31","value":-316000000,"profit":false},{"date":"2023-12-31","value":-6076300000,"profit":false}]
Gross Margin(47.43%)(390.93%)(5365.13%)(2953.27%)(823.46%)[{"date":"2019-12-31","value":-47.43,"profit":false},{"date":"2020-12-31","value":-390.93,"profit":false},{"date":"2021-12-31","value":-5365.13,"profit":false},{"date":"2022-12-31","value":-2953.27,"profit":false},{"date":"2023-12-31","value":-823.46,"profit":false}]
Operating Expenses20.73M35.06M70.64M110.44M90.73M[{"date":"2019-12-31","value":18.77,"profit":true},{"date":"2020-12-31","value":31.75,"profit":true},{"date":"2021-12-31","value":63.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.15,"profit":true}]
Operating Income(15.79M)(30.17M)(72.75M)(114.59M)(83.35M)[{"date":"2019-12-31","value":-1578500000,"profit":false},{"date":"2020-12-31","value":-3017000000,"profit":false},{"date":"2021-12-31","value":-7275200000,"profit":false},{"date":"2022-12-31","value":-11458700000,"profit":false},{"date":"2023-12-31","value":-8334700000,"profit":false}]
Total Non-Operating Income/Expense(7.29M)(3.61M)990.00K6.84M2.35M[{"date":"2019-12-31","value":-106.61,"profit":false},{"date":"2020-12-31","value":-52.81,"profit":false},{"date":"2021-12-31","value":14.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.34,"profit":true}]
Pre-Tax Income(18.16M)(31.98M)(70.36M)(107.69M)(82.20M)[{"date":"2019-12-31","value":-1815500000,"profit":false},{"date":"2020-12-31","value":-3198200000,"profit":false},{"date":"2021-12-31","value":-7036300000,"profit":false},{"date":"2022-12-31","value":-10769100000,"profit":false},{"date":"2023-12-31","value":-8220400000,"profit":false}]
Income Taxes490.00K238.00K107.00K67.00K261.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":48.57,"profit":true},{"date":"2021-12-31","value":21.84,"profit":true},{"date":"2022-12-31","value":13.67,"profit":true},{"date":"2023-12-31","value":53.27,"profit":true}]
Income After Taxes(18.64M)(32.22M)(70.47M)(107.76M)(82.47M)[{"date":"2019-12-31","value":-1864500000,"profit":false},{"date":"2020-12-31","value":-3222000000,"profit":false},{"date":"2021-12-31","value":-7047000000,"profit":false},{"date":"2022-12-31","value":-10775800000,"profit":false},{"date":"2023-12-31","value":-8246500000,"profit":false}]
Income From Continuous Operations(18.64M)(32.22M)(70.47M)(107.76M)(82.47M)[{"date":"2019-12-31","value":-1864500000,"profit":false},{"date":"2020-12-31","value":-3222000000,"profit":false},{"date":"2021-12-31","value":-7047000000,"profit":false},{"date":"2022-12-31","value":-10775800000,"profit":false},{"date":"2023-12-31","value":-8246500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(18.64M)(32.22M)(70.47M)(107.76M)(82.47M)[{"date":"2019-12-31","value":-1864500000,"profit":false},{"date":"2020-12-31","value":-3222000000,"profit":false},{"date":"2021-12-31","value":-7047000000,"profit":false},{"date":"2022-12-31","value":-10775800000,"profit":false},{"date":"2023-12-31","value":-8246500000,"profit":false}]
EPS (Diluted)(1.02)(0.35)(0.58)(0.84)(0.58)[{"date":"2019-12-31","value":-102,"profit":false},{"date":"2020-12-31","value":-35,"profit":false},{"date":"2021-12-31","value":-58,"profit":false},{"date":"2022-12-31","value":-84,"profit":false},{"date":"2023-12-31","value":-58,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VXRT
Cash Ratio 0.73
Current Ratio 0.83
Quick Ratio 0.88

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VXRT
ROA (LTM) -39.68%
ROE (LTM) -91.66%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VXRT
Debt Ratio Lower is generally better. Negative is bad. 0.59
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.41

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VXRT
Trailing PE NM
Forward PE 42.73
P/S (TTM) 9.65
P/B 1.96
Price/FCF NM
EV/R 4.66
EV/Ebitda NM

FAQs

What is Vaxart Inc share price today?

Vaxart Inc (VXRT) share price today is $0.563

Can Indians buy Vaxart Inc shares?

Yes, Indians can buy shares of Vaxart Inc (VXRT) on Vested. To buy Vaxart Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VXRT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Vaxart Inc be purchased?

Yes, you can purchase fractional shares of Vaxart Inc (VXRT) via the Vested app. You can start investing in Vaxart Inc (VXRT) with a minimum investment of $1.

How to invest in Vaxart Inc shares from India?

You can invest in shares of Vaxart Inc (VXRT) via Vested in three simple steps:

  • Click on Sign Up or Invest in VXRT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Vaxart Inc shares
What is Vaxart Inc 52-week high and low stock price?

The 52-week high price of Vaxart Inc (VXRT) is $1.54. The 52-week low price of Vaxart Inc (VXRT) is $0.52.

What is Vaxart Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Vaxart Inc (VXRT) is

What is Vaxart Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Vaxart Inc (VXRT) is 1.96

What is Vaxart Inc dividend yield?

The dividend yield of Vaxart Inc (VXRT) is 0.00%

What is the Market Cap of Vaxart Inc?

The market capitalization of Vaxart Inc (VXRT) is $134.37M

What is Vaxart Inc’s stock symbol?

The stock symbol (or ticker) of Vaxart Inc is VXRT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top